TouchNEUROLOGY recently spoke with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, US), to discuss the results from the phase 2 Huntington’s disease trial of anti-semaphorin 4D antibody pepinemab (SIGNAL). The interview was filmed at the virtual 15 International Conference for Alzheimer’s & Parkinson’s Diseases (ADPD), earlier this year. You can watch it, here:
